Skip to content
Dupixent(dupilumab)
Dupixent (dupilumab) is an antibody pharmaceutical. Dupilumab was first approved as Dupixent on 2017-03-28. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat asthma, atopic dermatitis, esophageal diseases, prurigo, and sinusitis. The pharmaceutical is active against interleukin-4 receptor subunit alpha. In addition, it is known to target Interleukin 4 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Dupixent
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Dupilumab
Tradename
Proper name
Company
Number
Date
Products
DupixentdupilumabRegeneron PharmaceuticalsN-761055 RX2017-03-28
5 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
dupixentBiologic Licensing Application2021-01-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atopic dermatitisEFO_0000274D003876L20
Agency Specific
FDA
EMA
Expiration
Code
dupilumab, Dupixent, Regeneron Pharmaceuticals, Inc.
2029-05-20Orphan excl.
Patent Expiration
No data
ATC Codes
D: Dermatologicals
D11: Other dermatological preparations in atc
D11A: Other dermatological preparations in atc
D11AH: Agents for dermatitis, excluding corticosteroids
D11AH05: Dupilumab
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L2041016201059
AsthmaD001249EFO_0000270J451689731
Nasal polypsD009298HP_0100582J33224513
EczemaD004485HP_0000964L30.91146
Eosinophilic esophagitisD057765EFO_0004232K20.012115
Allergic contact dermatitisD017449L231112
KeloidD007627EFO_0004212L91.0112
Lamellar ichthyosisD017490Q8011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bullous pemphigoidD010391EFO_0007187L121123
Chronic urticariaD000080223L50.8123
DermatitisD003872HP_0011123L30.9123
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.922
PruritusD011537HP_0000989L29112
NeurodermatitisD009450L28.022
Immune system diseasesD007154D89.922
Skin diseasesD012871L00-L99112
Eczematous skin diseasesD01744322
HypersensitivityD006967EFO_0003785T78.40112
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Peanut hypersensitivityD021183EFO_000742533
Alopecia areataD000506EFO_0004192L6322
Respiration disordersD012120J00-J9911
SinusitisD012852EFO_0007486J3211
Allergic conjunctivitisD003233EFO_0007141H10.4411
Allergic rhinitis seasonalD006255EFO_0003956J3011
EosinophiliaD004802HP_0001880D72.111
KeratoconjunctivitisD007637H16.211
Localized sclerodermaD012594L94.011
Prostatic neoplasmsD011471C6111
Show 8 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients44
Sleep apnea syndromesD012891EFO_0003877G47.311
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L4011
ConjunctivitisD003231H1011
Staphylococcus aureusD013211NCBITaxon_128011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDUPILUMAB
INNdupilumab
Description
Dupilumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)DUPILUMAB
Structure (InChI/SMILES or Protein Sequence)
>6WG8:A|Dupilumab Fab heavy chain EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLY LQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGHHHHHH >6WG8:B|Dupilumab Fab light chain DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKI SRVEAEDVGFYYCMQALQTPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTQGTTSVTKSFNRGEC
Identifiers
PDB6WG8, 6WGB, 6WGJ, 6WGK, 6WGL
CAS-ID1190264-60-8
RxCUI1876376
ChEMBL IDCHEMBL2108675
ChEBI ID
PubChem CID
DrugBankDB12159
UNII ID420K487FSG (ChemIDplus, GSRS)
Target
Agency Approved
IL4R
IL4R
Organism
Homo sapiens
Gene name
IL4R
Gene synonyms
IL4RA
NCBI Gene ID
Protein name
interleukin-4 receptor subunit alpha
Protein synonyms
CD124, IL-4 receptor subunit alpha, interleukin 13 receptor, interleukin-4 receptor alpha chain
Uniprot ID
Mouse ortholog
Il4ra (16190)
interleukin-4 receptor subunit alpha (Q8CBW5)
Alternate
IL4R
IL4R
Organism
Homo sapiens
Gene name
IL4R
Gene synonyms
NCBI Gene ID
Protein name
Interleukin 4 receptor
Protein synonyms
Uniprot ID
Mouse ortholog
Variants
Clinical Variant
No data
Financial
Dupixent - Sanofi
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Dupixent - Regeneron Pharmaceuticals
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,245 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
44,077 adverse events reported
View more details